Team

_

Michael Schlamp

Mike has more than 20 years of experience in biopharma commercialization and business development on both the industry side (Actelion, Genentech, Acologix) and the consulting side (ZS Associates). He has experience in commercial strategy, market research, forecasting, launch planning, and reimbursement planning for a range of programs from in-line to pre-IND. He has assisted companies ranging from Fortune 100 Big Pharmas to private biotechs across a wide range of therapeutic areas (including oncology, CNS, pain, cardiology, pulmonary hypertension, immunology, asthma/ COPD, nephrology, neurodegenerative disease, gastroenterology, and ultra-orphan). Mike has a BS from MIT and a Ph.D. in Chemistry from the University of California, Berkeley.

Reid Bengard

Reid started conducting market research for biotechnology and pharmaceutical companies in 1997. His experience spans qualitative and quantitative studies across dozens of therapeutic categories, including actinic keratosis, anemia, bone fracture, breast cancer, CRC, diabetes, NSCLC, hemophilia, lymphomas, multiple myeloma, MS, neutropenia, prostate cancer, pain, psoriasis, and RA, among others. Prior to starting Aquest, Reid held senior positions at ZS Associates and Ziment. Reid has a BS from the University of California at Davis and an MBA from the Wharton School of the University of Pennsylvania.

Suzanne Ochoa

Suzanne brings over 20 years of experience in pharmaceuticals, medical devices/hospital equipment, and veterinary medicine. Her functional expertise includes developing and managing market research across the product lifespan, as well as strategic support for commercial development and marketing teams. Suzanne started her career at Pfizer, Inc., where she held positions in Market Research, Brand Management and Regional Marketing. On the consulting side, she has worked with big Pharma clients, as well as biotech startups, on diverse therapeutic categories, including CNS, cardiology and metabolic disorders, infectious diseases, oncology and rare diseases. Suzanne holds a B.A. in English from Oberlin College, a Ph.D. in Anthropology from New York University, and a M.B.A. in Marketing from New York University, Stern School of Business.

Luis Chia, PhD

Luis is a seasoned marketing researcher and strategist with experience supporting brand commercialization strategy and execution. His recent work has focused on opportunity assessments, demand assessments, patient journey/buying process research, positioning and messaging development, and objection handling research to inform pre-launch and go-to-market strategies. His main areas of expertise are in hematology, oncology, neuropsychiatry and rare disease. Prior to joining Aquest Consulting, Luis was at BluePrint Research Group and Charles River Associates/C1 Consulting where he advised global pharmaceutical and biotechnology clients. He also Co-founded a biotechnology company that designs and manufactures dynamic tissue culture systems. Luis has a BA in Biology from the University of Pennsylvania and PhD in Cancer Biology from Stanford University.

 

Jim Thompson

Jim has more than 20 years of international pharmaceutical and biopharmaceutical strategy consulting experience. His areas of expertise are business planning, launch planning, market research and business development and has worked across a broad range of therapeutic areas, including autoimmune disorders, nephrology, neurology, oncology, ophthalmology, pulmonology and infectious diseases. Before joining Aquest, Jim was a Director with Navigant Consulting’s Life Science Strategy Practice. Prior to his role at Navigant, he was a Partner at Front Line Strategic Consulting and was instrumental in its growth and sale to Navigant Consulting. Jim has an MBA from U.C. Berkeley and a BA in molecular biology from San Jose State University.

Alan Aimi

Alan has more than 20 years in biotechnology commercial strategic planning, commercialization and business development. He has worked at Actelion, Genentech and Hyperion Therapeutics in the areas of launch planning; launch execution, life cycle planning and market assessments/in-licensing. Alan has successfully led launches in immunology and ultra-orphan diseases and has experience in numerous other therapeutic areas including oncology, neurology, pulmonology, cardiology, nephrology and rheumatology. Alan has a B.S. from the University of Colorado and an MBA from the University of Queensland, Australia.

Michael Schlamp

Mike has more than 20 years of experience in biopharma commercialization and business development on both the industry side (Actelion, Genentech, Acologix) and the consulting side (ZS Associates). He has experience in commercial strategy, market research, forecasting, launch planning, and reimbursement planning for a range of programs from in-line to pre-IND. He has assisted companies ranging from Fortune 100 Big Pharmas to private biotechs across a wide range of therapeutic areas (including oncology, CNS, pain, cardiology, pulmonary hypertension, immunology, asthma/ COPD, nephrology, neurodegenerative disease, gastroenterology, and ultra-orphan). Mike has a BS from MIT and a Ph.D. in Chemistry from the University of California, Berkeley.

Reid Bengard

Reid started conducting market research for biotechnology and pharmaceutical companies in 1997. His experience spans qualitative and quantitative studies across dozens of therapeutic categories, including actinic keratosis, anemia, bone fracture, breast cancer, CRC, diabetes, NSCLC, hemophilia, lymphomas, multiple myeloma, MS, neutropenia, prostate cancer, pain, psoriasis, and RA, among others. Prior to starting Aquest, Reid held senior positions at ZS Associates and Ziment. Reid has a BS from the University of California at Davis and an MBA from the Wharton School of the University of Pennsylvania.

Suzanne Ochoa

Suzanne brings over 20 years of experience in pharmaceuticals, medical devices/hospital equipment, and veterinary medicine. Her functional expertise includes developing and managing market research across the product lifespan, as well as strategic support for commercial development and marketing teams. Suzanne started her career at Pfizer, Inc., where she held positions in Market Research, Brand Management and Regional Marketing. On the consulting side, she has worked with big Pharma clients, as well as biotech startups, on diverse therapeutic categories, including CNS, cardiology and metabolic disorders, infectious diseases, oncology and rare diseases. Suzanne holds a B.A. in English from Oberlin College, a Ph.D. in Anthropology from New York University, and a M.B.A. in Marketing from New York University, Stern School of Business.

Luis Chia, PhD

Luis is a seasoned marketing researcher and strategist with experience supporting brand commercialization strategy and execution. His recent work has focused on opportunity assessments, demand assessments, patient journey/buying process research, positioning and messaging development, and objection handling research to inform pre-launch and go-to-market strategies. His main areas of expertise are in hematology, oncology, neuropsychiatry and rare disease. Prior to joining Aquest Consulting, Luis was at BluePrint Research Group and Charles River Associates/C1 Consulting where he advised global pharmaceutical and biotechnology clients. He also Co-founded a biotechnology company that designs and manufactures dynamic tissue culture systems. Luis has a BA in Biology from the University of Pennsylvania and PhD in Cancer Biology from Stanford University.

 

Jim Thompson

Jim has more than 20 years of international pharmaceutical and biopharmaceutical strategy consulting experience. His areas of expertise are business planning, launch planning, market research and business development and has worked across a broad range of therapeutic areas, including autoimmune disorders, nephrology, neurology, oncology, ophthalmology, pulmonology and infectious diseases. Before joining Aquest, Jim was a Director with Navigant Consulting’s Life Science Strategy Practice. Prior to his role at Navigant, he was a Partner at Front Line Strategic Consulting and was instrumental in its growth and sale to Navigant Consulting. Jim has an MBA from U.C. Berkeley and a BA in molecular biology from San Jose State University.

Alan Aimi

Alan has more than 20 years in biotechnology commercial strategic planning, commercialization and business development. He has worked at Actelion, Genentech and Hyperion Therapeutics in the areas of launch planning; launch execution, life cycle planning and market assessments/in-licensing. Alan has successfully led launches in immunology and ultra-orphan diseases and has experience in numerous other therapeutic areas including oncology, neurology, pulmonology, cardiology, nephrology and rheumatology. Alan has a B.S. from the University of Colorado and an MBA from the University of Queensland, Australia.